top of page
Search
Compass Pathways Hits Milestone in Psychedelic Drug Development with Phase 3 Psilocybin Readout for 250+ Patients
Compass Pathways has become the first company to publish Phase 3 data for a classical psychedelic. Its synthetic psilocybin candidate,...
2 hours ago
Psilocybin for Depression: A Closer Look at the Evidence
With the rise of companies exploring psilocybin based drugs to treat various mental health conditions, the need for greater evidence...
May 19
Microdosing Psilocybin for Women’s Health: Endometriosis, PMDD & Menopause | Mabel
Mabel: Microdosing Psilocybin for Women’s Health
Apr 6
Could Psychedelic Therapies Offer New Hope for Alzheimer's Disease?
Alzheimer’s Disease (AD) is a pressing global challenge, with cases expected to triple globally, affecting around 152 million people by...
Mar 29
Research: Psilocybin Microdosing Boosts Emotional Stability and Reduces Depression and Anxiety Symptoms.
The global burden of mental health disorders is rising, with depression and anxiety leading the charge as major contributors to...
Feb 7
bottom of page